Literature DB >> 17332095

Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision.

Benjamin K Potter1, Travis C Burns, Anton P Lacap, Robert R Granville, Donald A Gajewski.   

Abstract

BACKGROUND: Although infrequently reported in amputees previously, heterotopic ossification has proven to be a common and problematic clinical entity in our recent experience in the treatment of traumatic and combat-related amputations related to Operation Enduring Freedom and Operation Iraqi Freedom. The purpose of the present study was to report the prevalence of and risk factors for heterotopic ossification following trauma-related amputation as well as the preliminary results of operative excision.
METHODS: We identified 330 patients with a total of 373 traumatic and combat-related amputations who had been managed at our centers between September 11, 2001 and November 30, 2005. We reviewed the medical records and radiographs of 187 patients with 213 amputations who had adequate radiographic follow-up. Additional analysis was performed for twenty-four patients with twenty-five limbs that required excision of symptomatic lesions. The mechanism and zone of injury, amputation level, timing of excision, use of prophylaxis against recurrence, and other confounding variables were examined. Outcomes were assessed by determining clinical and radiographic recurrence rates, perioperative complications, preoperative and follow-up pain medication requirements, and the ability to be fit with a functional prosthesis.
RESULTS: Heterotopic ossification was present in 134 (63%) of 213 residual limbs, with twenty-five lesions requiring excision. A final amputation level within the zone of injury was a risk factor for both the development and the grade of heterotopic ossification (p < 0.05). A blast mechanism was predictive of occurrence (p < 0.05) but did not correlate with grade. All patients who had been managed with excision were tolerating the prosthetic limb at an average of twelve months of follow-up. Twenty-three limbs demonstrated no evidence of recurrence, and two limbs had development of clinically asymptomatic, radiographically minimal recurrences. Six patients experienced wound-related complications that required reoperation, and two patients required subsequent minor revision surgery. There was a significant decrease in the use of pain medication following surgery (p < 0.05).
CONCLUSIONS: Heterotopic ossification following trauma-related amputation is more common than the literature would suggest, particularly following amputations that are performed within the initial zone of injury and those that are due to blast injuries. Many patients are asymptomatic or can be successfully managed with modification of the prosthesis. For patients with refractory symptoms, surgical excision is associated with low recurrence rates and decreased medication requirements, with acceptable complication rates.

Entities:  

Mesh:

Year:  2007        PMID: 17332095     DOI: 10.2106/JBJS.F.00412

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  82 in total

1.  Developing a quantitative measurement system for assessing heterotopic ossification and monitoring the bioelectric metrics from electrically induced osseointegration in the residual limb of service members.

Authors:  Brad M Isaacson; Jeroen G Stinstra; Rob S MacLeod; Paul F Pasquina; Roy D Bloebaum
Journal:  Ann Biomed Eng       Date:  2010-05-11       Impact factor: 3.934

2.  Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification.

Authors:  Michael N Wosczyna; Arpita A Biswas; Catherine A Cogswell; David J Goldhamer
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

3.  Treatment for a femoral shaft bone defect using heterotopic bone formation as autograft.

Authors:  Jin Park; Jung Ryul Kim; Kyu Hyun Yang
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-09-09

4.  What Risk Factors Predict Recurrence of Heterotopic Ossification After Excision in Combat-related Amputations?

Authors:  Gabriel J Pavey; Elizabeth M Polfer; Kyle E Nappo; Scott M Tintle; Jonathan A Forsberg; Benjamin K Potter
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

5.  Functional outcome after excision of heterotopic ossification about the knee in ICU patients.

Authors:  G I Mitsionis; M G Lykissas; N Kalos; N Paschos; A E Beris; A D Georgoulis; T A Xenakis
Journal:  Int Orthop       Date:  2008-07-19       Impact factor: 3.075

6.  Differentiation potential of multipotent progenitor cells derived from war-traumatized muscle tissue.

Authors:  Leon J Nesti; Wesley M Jackson; Rabie M Shanti; Steven M Koehler; Amber B Aragon; James R Bailey; Michael K Sracic; Brett A Freedman; Jeffrey R Giuliani; Rocky S Tuan
Journal:  J Bone Joint Surg Am       Date:  2008-11       Impact factor: 5.284

7.  Mesenchymal progenitor cells derived from traumatized human muscle.

Authors:  W M Jackson; A B Aragon; F Djouad; Y Song; S M Koehler; L J Nesti; R S Tuan
Journal:  J Tissue Eng Regen Med       Date:  2009-02       Impact factor: 3.963

8.  Preventing Heterotopic Ossification in Combat Casualties-Which Models Are Best Suited for Clinical Use?

Authors:  Keith A Alfieri; Benjamin K Potter; Thomas A Davis; Matthew B Wagner; Eric A Elster; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

Review 9.  Multimodality imaging review of the post-amputation stump pain.

Authors:  Nawaraj Subedi; Priam Heire; Vinay Parmer; Simon Beardmore; Chooi Oh; Fergus Jepson; Syed I Ali
Journal:  Br J Radiol       Date:  2016-09-29       Impact factor: 3.039

10.  Putative heterotopic ossification progenitor cells derived from traumatized muscle.

Authors:  Wesley M Jackson; Amber B Aragon; Jamie D Bulken-Hoover; Leon J Nesti; Rocky S Tuan
Journal:  J Orthop Res       Date:  2009-12       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.